Lucid’s LucidDx Labs signs deal with MediNcrease

2020 03 16 19 06 1700 Insurance Coverage 400

Pavmed subsidiary Lucid Diagnostics announced that its laboratory LucidDx Labs has signed a deal to supply its EsoGuard DNA test to members of MediNcrease Health Plans.

This is Lucid's first agreement with a commercial payer. The deal will provide in-network access and payment for Lucid's EsoGuard DNA test to those insured by MediNcrease. The health insurance plan currently provides coverage to 8 million people.

The EsoGuard test is a tool that helps prevent esophageal cancer deaths through the early detection of esophageal precancer in at-risk chronic heartburn patients.

Page 1 of 15
Next Page